Illumina, Inc. $ILMN Shares Sold by North Dakota State Investment Board

North Dakota State Investment Board reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 77.2% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,653 shares of the life sciences company’s stock after selling 15,795 shares during the quarter. North Dakota State Investment Board’s holdings in Illumina were worth $1,273,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in ILMN. BlackRock Inc. acquired a new position in Illumina in the 2nd quarter valued at approximately $3,374,423,000. Primecap Management Co. CA acquired a new stake in shares of Illumina during the 2nd quarter valued at $617,981,000. Jupiter Topco LLC acquired a new stake in shares of Illumina during the 2nd quarter valued at $358,652,000. WCM Investment Management LLC boosted its stake in shares of Illumina by 45.5% during the 1st quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after buying an additional 1,851,848 shares during the period. Finally, Bank of New York Mellon Corp purchased a new position in shares of Illumina during the 2nd quarter valued at $293,846,000. 89.42% of the stock is owned by hedge funds and other institutional investors.

More Illumina News

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Adjusted earnings exceeded expectations. Illumina reported third-quarter adjusted EPS of $1.44, above the $1.36 consensus estimate, while revenue increased 4.2% year over year to approximately $1.13 billion. Illumina Reports Financial Results for Third Quarter
• Positive Sentiment: Full-year guidance was raised. Management increased its 2026 outlook, with revenue guidance of roughly $4.65 billion at the midpoint, supported by clinical sequencing demand and continued adoption of the NovaSeq X platform. ILMN Q3 Earnings Call Highlights
• Positive Sentiment: Long-term industry demand remains favorable. Recent market reports point to strong growth in clinical genomics, sequencing-as-a-service, population screening, and AI-enabled genomic analysis—markets in which Illumina is a major participant. These reports are industry forecasts rather than new company contracts or financial commitments.
• Neutral Sentiment: Analyst sentiment became more cautious. JPMorgan reduced its price target from $320 to $300, while Robert W. Baird maintained a Hold rating. The target cut suggests less near-term upside following Illumina’s substantial prior rally. JPMorgan Adjusts Price Target
• Negative Sentiment: Revenue performance disappointed investors. Although earnings surpassed estimates, quarterly revenue was below consensus in several reports, highlighting softer demand than expected and limiting the impact of the profit beat.
• Negative Sentiment: China exposure, tariffs, and business mix remain concerns. Investors are worried about China-related revenue challenges, tariff uncertainty, research-market weakness, and pricing pressure. A broader pullback in AI-linked technology stocks also hurt sentiment toward Illumina. Illumina Shares Tumble on China Woes

Insiders Place Their Bets

In other Illumina news, Director Keith Meister sold 457,858 shares of the business’s stock in a transaction dated Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total value of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company’s stock, valued at $474,776,069.40. The trade was a 16.18% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders sold 2,061,235 shares of company stock worth $436,356,102 in the last 90 days. 2.90% of the stock is owned by company insiders.

Illumina Stock Down 18.6%

Illumina stock opened at $235.99 on Friday. The company has a current ratio of 1.80, a quick ratio of 1.40 and a debt-to-equity ratio of 0.53. Illumina, Inc. has a 1-year low of $106.12 and a 1-year high of $309.35. The firm’s fifty day simple moving average is $249.30 and its 200-day simple moving average is $176.18. The company has a market capitalization of $35.63 billion, a P/E ratio of 40.62, a P/E/G ratio of 4.11 and a beta of 1.41.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings data on Thursday, October 29th. The life sciences company reported $1.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.36 by $0.26. The firm had revenue of $1.17 billion during the quarter, compared to analysts’ expectations of $1.15 billion. Illumina had a net margin of 19.72% and a return on equity of 29.41%. Illumina’s revenue for the quarter was up 4.2% on a year-over-year basis. During the same period in the prior year, the company posted $1.34 earnings per share. Sell-side analysts forecast that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ILMN has been the topic of several research analyst reports. Evercore reaffirmed an “underperform” rating on shares of Illumina in a research note on Friday. TD Cowen increased their price objective on Illumina from $210.00 to $270.00 and gave the stock a “hold” rating in a report on Tuesday, October 13th. Canaccord Genuity Group lifted their price objective on Illumina from $205.00 to $300.00 and gave the company a “hold” rating in a research report on Monday, October 19th. Argus boosted their target price on Illumina from $180.00 to $235.00 and gave the company a “buy” rating in a research note on Thursday, September 3rd. Finally, Sanford C. Bernstein restated a “market perform” rating and issued a $215.00 target price on shares of Illumina in a research note on Friday, July 31st. Nine research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $238.53.

Illumina Company Profile

Illumina, Inc is a biotechnology company that develops and manufactures genomics and genetic-analysis technologies. Its products are used to study DNA and RNA in applications including biomedical research, clinical testing, pharmaceutical development, reproductive health, oncology and population genomics.

The company’s offerings include next-generation sequencing systems, consumable flow cells and reagent kits, microarrays, and genomic data-analysis software. Its sequencing portfolio includes instruments such as the NovaSeq, NextSeq, MiSeq and iSeq platforms, while its informatics products include the DRAGEN platform, which supports the processing and interpretation of sequencing data.